{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:10:41Z","timestamp":1789657841291,"version":"4.0.1"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Advanced aniridia-related keratopathy (ARK) is a progressive ocular surface disorder associated with limbal stem cell deficiency and limited effective treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety, feasibility, and clinical outcomes of Real Architecture for 3D Tissues\u2013Ocular Surface (RAFT-OS), a tissue-engineered collagen scaffold incorporating allogeneic limbal epithelial stem cells and stromal keratocytes, in adults with advanced ARK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This single-arm, open-label nonrandomized clinical trial was conducted at a tertiary referral center in London, United Kingdom. Adults with congenital aniridia and advanced ARK underwent RAFT-OS transplant. Untreated fellow eyes served as natural history comparators. Recruitment occurred between February 2022 and April 2024, with final study completion in April 2025. Follow-up was 12 months. Data analysis was performed from May 2025 through February 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Surgical transplant of a good manufacturing practice\u2013manufactured RAFT-OS construct.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end points were safety and ocular surface normalization at 3 and 12 months, assessed using the Ocular Surface Score (OSS). Secondary outcomes included best-corrected visual acuity (BCVA, via Early Treatment Diabetic Retinopathy Study [ETDRS] acuity charts) and patient-reported outcomes (Visual Function Questionnaire [VFQ-25], 36-Item Short Form Survey [RAND-36]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine participants were included (3 female [33%]; mean [SD] age, 50.6 [11.6] years). One early serious adverse event prompted amendment of the manufacturing protocol; no further major RAFT-OS\u2013related safety events occurred. Two participants developed persistent epithelial defects. In treated eyes, mean (SD) OSS was 9.4 (1.9) at baseline, 5.9 (2.4) at 3 months (mean difference from baseline, \u22123.6; 95% CI, \u22125.6 to \u22121.6), and 6.7 (2.4) at 12 months (mean difference, \u22122.8; 95% CI, \u22124.5 to \u22121.0). In untreated fellow eyes, mean (SD) OSS was 8.4 (2.7) at baseline, 8.4 (2.4) at 3 months (mean difference, 0; 95% CI, \u22122.5 to 2.5), and 8.0 (2.5) at 12 months (mean difference, \u22120.4; 95% CI, \u22122.4 to 1.5). Mean (SD) treated eye BCVA was 2.23 (0.16) logMAR (Snellen equivalent, &amp;amp;lt;20\/1600) at baseline and 1.77 (0.67) logMAR (20\/1280) at 12 months (mean difference, \u22120.47; 95% CI, \u22120.97 to 0.04). Mean (SD) fellow eye BCVA was 1.47 (0.71) logMAR (Snellen equivalent, 20\/640) at baseline and 1.44 (0.75) logMAR (20\/640) at 12 months (mean difference, \u22120.04; 95% CI, \u22120.44 to 0.37).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this 9-participant nonrandomized clinical trial, RAFT-OS transplant was feasible and associated with early ocular surface improvement, partly sustained through 12 months, without substantial safety concerns. Additional controlled studies with longer follow-up are needed to define safety and clinical effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05044598?cond=NCT05044598&amp;amp;amp;viewType=Card&amp;amp;amp;rank=1\">NCT05044598<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.2701","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:30:35Z","timestamp":1784820635000},"page":"812","source":"Crossref","is-referenced-by-count":0,"title":["Combined Limbal Epithelial and Stromal Cell Transplant for Aniridia-Related Keratopathy"],"prefix":"10.1001","volume":"144","author":[{"given":"Abigail Eve","family":"Kaye","sequence":"first","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom"},{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Morgan","sequence":"additional","affiliation":[{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Shah","sequence":"additional","affiliation":[{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Vernon","sequence":"additional","affiliation":[{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Embleton-Thirsk","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim-Moulay","family":"Dehbi","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sibley","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Oreaba","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie T.","family":"Daniels","sequence":"additional","affiliation":[{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom"},{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi260040r1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5966\/sctm.2013-0025","article-title":"Three-year outcomes of cultured limbal epithelial allografts in aniridia and Stevens-Johnson syndrome evaluated using the Clinical Outcome Assessment in Surgical Trials assessment tool.","volume":"3","author":"Shortt","year":"2014","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"eoi260040r2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1096\/fj.04-2770fje","article-title":"PAX6 expression identifies progenitor cells for corneal keratocytes.","volume":"19","author":"Funderburgh","year":"2005","journal-title":"FASEB J"},{"issue":"5","key":"eoi260040r3","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1167\/iovs.02-0576","article-title":"Corneal abnormalities in Pax6+\/- small eye mice mimic human aniridia-related keratopathy.","volume":"44","author":"Ramaesh","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"eoi260040r4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198822","article-title":"Aniridia-related keratopathy: structural changes in na\u00efve and transplanted corneal buttons.","volume":"13","author":"Vicente","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"eoi260040r5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/jfb6010050","article-title":"Tissue engineering the cornea: the evolution of RAFT.","volume":"6","author":"Levis","year":"2015","journal-title":"J Funct Biomater"},{"key":"eoi260040r6","doi-asserted-by":"publisher","first-page":"16186","DOI":"10.1038\/srep16186","article-title":"Human corneal stromal stem cells support limbal epithelial cells cultured on RAFT tissue equivalents.","volume":"5","author":"Kureshi","year":"2015","journal-title":"Sci Rep"},{"key":"eoi260040r7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.actbio.2015.06.007","article-title":"Optimization of optical and mechanical properties of real architecture for 3-dimensional tissue equivalents: towards treatment of limbal epithelial stem cell deficiency.","volume":"24","author":"Massie","year":"2015","journal-title":"Acta Biomater"},{"issue":"5","key":"eoi260040r8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.survophthal.2023.04.003","article-title":"Future directions in managing aniridia-associated keratopathy.","volume":"68","author":"van Velthoven","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"eoi260040r9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jtos.2017.11.003","article-title":"Stage-related central corneal epithelial transformation in congenital aniridia-associated keratopathy.","volume":"16","author":"Lagali","year":"2018","journal-title":"Ocul Surf"},{"issue":"7","key":"eoi260040r10","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ophtha.2006.10.029","article-title":"New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome.","volume":"114","author":"Sotozono","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi260040r11","doi-asserted-by":"publisher","first-page":"e963","DOI":"10.1111\/aos.14659","article-title":"A novel excel sheet conversion tool from Snellen fraction to logMAR including \u2018counting fingers\u2019, \u2018hand movement\u2019, \u2018light perception\u2019 and \u2018no light perception\u2019 and focused review of literature of low visual acuity reference values.","volume":"99","author":"Moussa","year":"2021","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"eoi260040r12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/0039-6257(84)90184-X","article-title":"Aniridia. a review.","volume":"28","author":"Nelson","year":"1984","journal-title":"Surv Ophthalmol"},{"key":"eoi260040r13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jtos.2021.09.001","article-title":"Pathophysiology of aniridia-associated keratopathy: developmental aspects and unanswered questions.","volume":"22","author":"Latta","year":"2021","journal-title":"Ocul Surf"},{"issue":"4","key":"eoi260040r14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/sctm.18-0140","article-title":"Allogeneic ex vivo expanded corneal epithelial stem cell transplantation: a randomized controlled clinical trial.","volume":"8","author":"Campbell","year":"2019","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"eoi260040r15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/bjo.2007.123026","article-title":"Amniotic membrane transplantation for the management of corneal epithelial defects: an in vivo confocal microscopic study.","volume":"92","author":"Nubile","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"eoi260040r16","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1167\/iovs.08-2923","article-title":"Survival of donor-derived cells in human corneal transplants.","volume":"50","author":"Lagali","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"46","key":"eoi260040r17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001022","article-title":"A biosynthetic alternative to human donor tissue for inducing corneal regeneration: 24-month follow-up of a phase 1 clinical study.","volume":"2","author":"Fagerholm","year":"2010","journal-title":"Sci Transl Med"},{"issue":"8","key":"eoi260040r18","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1016\/j.biomaterials.2013.11.079","article-title":"Stable corneal regeneration four years after implantation of a cell-free recombinant human collagen scaffold.","volume":"35","author":"Fagerholm","year":"2014","journal-title":"Biomaterials"},{"issue":"1","key":"eoi260040r19","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1038\/s41598-021-82678-3","article-title":"A decellularized human corneal scaffold for anterior corneal surface reconstruction.","volume":"11","author":"Polisetti","year":"2021","journal-title":"Sci Rep"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2851760\/jamaophthalmology_kaye_2026_oi_260040_1788898341.95059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:00:48Z","timestamp":1789657248000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2851760"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.2701","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}